The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...
Wegovy (semaglutide), a once-weekly GLP-1 agonist, has already overtaken Novo Nordisk's once-daily obesity therapy Saxenda (liraglutide) in terms of the number of physicians prescribing the two drugs.
Novo Nordisk (NVO) announced that the Food and ... along with its existing indications for adults with type 2 diabetes to improve glycemic control and to reduce the risk of major cardiovascular ...
The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug in its type 2 diabetes franchise. Rybelsus (semaglutide) is the first GLP-1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results